PDF(Pubmed)
Abstract：
UNASSIGNED: A novel systemic immune-inflammation index (SII), based on the neutrophils, lymphocytes, and platelet counts, is associated with the prognosis of several cancers, including non-metastatic renal cell carcinoma (RCC). In the present study, we evaluate the prognostic significance of SII in patients with metastatic RCC (mRCC) treated with systemic therapy.
UNASSIGNED: Relevant studies were searched comprehensively from Web of Science, PubMed, Embase and the Cochrane Library up to January 2024. The pooled hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study to evaluate the prognostic value of SII in patients with mRCC treated with tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI).
UNASSIGNED: A total of 12 studies including 4,238 patients were included in the final analysis. High SII was significantly correlated to poor overall survival (OS, HR = 1.88; 95% CI 1.60-2.21; P < 0.001) and progression-free survival (PFS, HR = 1.66; 95% CI 1.39-1.99; P < 0.001). Stratified by therapy, high SII was also related to the poor OS (TKI: HR = 1.63, P < 0.001; ICI: HR = 2.27, P < 0.001) and PFS (TKI: HR = 1.67, P < 0.001; ICI: HR = 1.88, P = 0.002).
UNASSIGNED: In conclusion, high SII could serve as an unfavorable factor in patients with mRCC treated with systemic therapy. Stratified by therapies, the elevated SII was also associated with worse prognosis. Whereas, more prospective and large-scale studies are warranted to validate our findings.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024522831, identifier CRD42024522831.
UNASSIGNED: Relevant studies were searched comprehensively from Web of Science, PubMed, Embase and the Cochrane Library up to January 2024. The pooled hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study to evaluate the prognostic value of SII in patients with mRCC treated with tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI).
UNASSIGNED: A total of 12 studies including 4,238 patients were included in the final analysis. High SII was significantly correlated to poor overall survival (OS, HR = 1.88; 95% CI 1.60-2.21; P < 0.001) and progression-free survival (PFS, HR = 1.66; 95% CI 1.39-1.99; P < 0.001). Stratified by therapy, high SII was also related to the poor OS (TKI: HR = 1.63, P < 0.001; ICI: HR = 2.27, P < 0.001) and PFS (TKI: HR = 1.67, P < 0.001; ICI: HR = 1.88, P = 0.002).
UNASSIGNED: In conclusion, high SII could serve as an unfavorable factor in patients with mRCC treated with systemic therapy. Stratified by therapies, the elevated SII was also associated with worse prognosis. Whereas, more prospective and large-scale studies are warranted to validate our findings.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024522831, identifier CRD42024522831.
摘要：
■一种新的全身免疫炎症指数（SII），基于中性粒细胞，淋巴细胞，和血小板计数,与几种癌症的预后有关，包括非转移性肾细胞癌（RCC）。在本研究中,我们评估了SII在接受全身性治疗的转移性RCC（mRCC）患者中的预后意义。
■相关研究从WebofScience进行了全面搜索，PubMed,截至2024年1月，Embase和Cochrane图书馆。从每项研究中提取合并风险比（HR）和95％置信区间（CI），以评估SII在接受酪氨酸激酶抑制剂（TKI）或免疫检查点抑制剂（ICI）治疗的mRCC患者中的预后价值。
■共有12项研究包括4,238名患者纳入最终分析。高SII与低总生存率显著相关(OS，HR=1.88；95%CI1.60-2.21；P<0.001）和无进展生存期（PFS，HR=1.66；95%CI1.39-1.99；P<0.001）。按治疗分层，高SII还与不良OS(TKI:HR=1.63,P<0.001;ICI:HR=2.27,P<0.001)和PFS(TKI:HR=1.67,P<0.001;ICI:HR=1.88,P=0.002)相关。
■总而言之，高SII可能是全身治疗mRCC患者的不利因素.按疗法分层，SII升高也与不良预后相关.然而,我们需要更多前瞻性和大规模的研究来验证我们的研究结果.
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD42024522831，标识符CRD42024522831。
■相关研究从WebofScience进行了全面搜索，PubMed,截至2024年1月，Embase和Cochrane图书馆。从每项研究中提取合并风险比（HR）和95％置信区间（CI），以评估SII在接受酪氨酸激酶抑制剂（TKI）或免疫检查点抑制剂（ICI）治疗的mRCC患者中的预后价值。
■共有12项研究包括4,238名患者纳入最终分析。高SII与低总生存率显著相关(OS，HR=1.88；95%CI1.60-2.21；P<0.001）和无进展生存期（PFS，HR=1.66；95%CI1.39-1.99；P<0.001）。按治疗分层，高SII还与不良OS(TKI:HR=1.63,P<0.001;ICI:HR=2.27,P<0.001)和PFS(TKI:HR=1.67,P<0.001;ICI:HR=1.88,P=0.002)相关。
■总而言之，高SII可能是全身治疗mRCC患者的不利因素.按疗法分层，SII升高也与不良预后相关.然而,我们需要更多前瞻性和大规模的研究来验证我们的研究结果.
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD42024522831，标识符CRD42024522831。
